CDH3 promotes the progression of lung adenocarcinoma through driving epithelial-mesenchymal transition progress
CDH3 drives LUAD progression by promoting EMT, tumor growth, metastasis, and immunosuppression. It represents a promising diagnostic/prognostic biomarker and a novel therapeutic target for LUAD immunotherapy.
Authors
- W.X. Gong (ORCID: https://orcid.org/0009-0004-1775-7322)
- Fushan Gao
- H H He (ORCID: https://orcid.org/0000-0001-7934-6976)
- Yibo Gao (ORCID: https://orcid.org/0000-0002-0501-9814)
- Jie He (ORCID: https://orcid.org/0000-0002-0285-5403)
- Fei Shao (ORCID: https://orcid.org/0009-0003-6413-9933)
- Zhen Zhang (ORCID: https://orcid.org/0009-0006-8239-6652)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1186/s12967-025-06750-6
- Citations
- 3
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- National Natural Science Foundation of China
- Sanming Project of Medicine in Shenzhen
- Shenzhen Science and Technology Innovation Program
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine